[EFFECTIVENESS OF FULLERENE-(TRIS-AMINOCAPRONIC ACID) HYDRATE IN THE MODEL OF EXPERIMENTAL VIRAL-BACTERIAL PNEUMONIA
Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii
|February 3, 2016
Summary
Fullerene-(tris-aminocapronic acid) hydrate (FTAAH) effectively treats experimental viral-bacterial pneumonia in mice. Injectable FTAAH improved survival and reduced viral and bacterial loads, demonstrating its therapeutic potential.
Area of Science:
- Pharmacology
- Infectious Diseases
- Nanomedicine
Context:
- Viral-bacterial pneumonia poses a significant health challenge.
- Influenza and Staphylococcus aureus co-infections create complex disease models.
- Evaluating novel therapeutic agents is crucial for combating resistant infections.
Purpose:
- To assess the efficacy of fullerene-(tris-aminocapronic acid) hydrate (FTAAH) and its formulations.
- To investigate FTAAH's effectiveness against a combined viral-bacterial pneumonia model in mice.
- To compare FTAAH with established antiviral and antibacterial treatments.
Summary:
- Mice infected with influenza A and Staphylococcus aureus were treated with injectable or rectal FTAAH, oseltamivir, or arbidol.
- Injectable FTAAH significantly improved survival rates, reduced weight loss, and decreased viral titers and bacterial lung density.
- Rectal FTAAH efficacy varied with dosage and infection protocol, showing dose-dependent improvements.
Impact:
- FTAAH demonstrates potent therapeutic effects in treating complex respiratory infections.
- Injectable FTAAH offers a promising new treatment strategy for viral-bacterial pneumonia.
- Further research into FTAAH formulations could lead to improved clinical outcomes.
